Search
Aprea Therapeutics Inc
APREAdd to Watchlist
0.741USD
-0.004-0.55%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
8.88MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Aprea Therapeutics Inc is 9.00, ranking 17 out of 387 in the Biotechnology & Medical Research industry. The average price target is 10.50, with a high of 11.00 and a low of 10.00.
Analyst Rating
Based on
4
analysts
Strong Buy
Current Rating
4.300
Target Price
+477.10%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Aprea Therapeutics Inc
APRE
4
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Aprea Therapeutics Inc's expected revenue for the next quarter?
Aprea Therapeutics Inc's expected revenue is 168.67K.
What is Aprea Therapeutics Inc's price target?
Analysts forecast that Aprea Therapeutics Inc's price target is USD 10.50, with the highest forecast at USD 11.00 and the lowest forecast at USD 10.00.
How have Aprea Therapeutics IncAPRE's recent earnings per share performed?
The market expectation was USD -0.22, while Aprea Therapeutics IncAPRE's earnings per share (EPS) for the previous quarter was USD -0.32. EPS for the next quarter is expected at USD -0.23.
What is the analyst rating for Aprea Therapeutics Inc?
Based on the ratings of Aprea Therapeutics Inc's stock from 4 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.